Abdelwahed, K.S.; Siddique, A.B.; Ebrahim, H.Y.; Qusa, M.H.; Mudhish, E.A.; Rad, A.H.; Zerfaoui, M.; Abd Elmageed, Z.Y.; El Sayed, K.A.
Pseurotin A Validation as a Metastatic Castration-Resistant Prostate Cancer Recurrence-Suppressing Lead via PCSK9-LDLR Axis Modulation. Mar. Drugs 2023, 21, 215.
https://doi.org/10.3390/md21040215
AMA Style
Abdelwahed KS, Siddique AB, Ebrahim HY, Qusa MH, Mudhish EA, Rad AH, Zerfaoui M, Abd Elmageed ZY, El Sayed KA.
Pseurotin A Validation as a Metastatic Castration-Resistant Prostate Cancer Recurrence-Suppressing Lead via PCSK9-LDLR Axis Modulation. Marine Drugs. 2023; 21(4):215.
https://doi.org/10.3390/md21040215
Chicago/Turabian Style
Abdelwahed, Khaldoun S., Abu Bakar Siddique, Hassan Y. Ebrahim, Mohammed H. Qusa, Ethar A. Mudhish, Ashkan H. Rad, Mourad Zerfaoui, Zakaria Y. Abd Elmageed, and Khalid A. El Sayed.
2023. "Pseurotin A Validation as a Metastatic Castration-Resistant Prostate Cancer Recurrence-Suppressing Lead via PCSK9-LDLR Axis Modulation" Marine Drugs 21, no. 4: 215.
https://doi.org/10.3390/md21040215
APA Style
Abdelwahed, K. S., Siddique, A. B., Ebrahim, H. Y., Qusa, M. H., Mudhish, E. A., Rad, A. H., Zerfaoui, M., Abd Elmageed, Z. Y., & El Sayed, K. A.
(2023). Pseurotin A Validation as a Metastatic Castration-Resistant Prostate Cancer Recurrence-Suppressing Lead via PCSK9-LDLR Axis Modulation. Marine Drugs, 21(4), 215.
https://doi.org/10.3390/md21040215
